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ABSTRACT
Progress in mesenchymal stem cell (MSC) based therapies for nucleus pulposus 
(NP) regeneration are hampered by a lack of understanding and consensus of the 
normal NP cell phenotype. Despite the recent consensus paper on NP markers, there 
is still a need to further validate proposed markers. This study aimed to determine 
whether an NP phenotypic profile could be identified within a large population of 
mature NP samples.
qRT-PCR was conducted to assess mRNA expression of 13 genes within human 
non-degenerate articular chondrocytes (AC) (n=10) and NP cells extracted from 
patients across a spectrum of histological degeneration grades (n=71). qRT-PCR 
results were used to select NP marker candidates for protein expression analysis. 
Differential expression at mRNA between AC and non-degenerate NP cells was 
only observed for Paired Box Protein 1 (PAX1) and Forkhead box F1 (FOXF1). In 
contrast no other previously suggested markers displayed differential expression 
between non-degenerate NP and AC at mRNA level. PAX1 and FOXF1 protein 
expression was significantly higher in the NP compared to annulus fibrosus (AF), 
cartilaginous endplate (CEP) and AC. In contrast Laminin-5 (LAM-332), Keratin-19 
(KRT-19) and Hypoxia Inducible Factor 1 alpha (HIF1α) showed no differential 
expression in NP cells compared with AC cells. 
A marker which exclusively differentiates NP cells from AF and AC cells remains 
to be identified, raising the question: is the NP a heterogeneous population of cells? 
Or does the natural biological variation during IVD development, degeneration state 
and even the life cycle of cells make finding one definitive marker impossible?
INTRODUCTION
Low back pain (LBP) is one of the most prevalent 
health problems in the western world [1, 2], with 
degeneration of the intervertebral disc (IVD) implicated 
in 40% of cases [3, 4]. Current surgical treatments have 
been directed towards alleviating patient symptoms[5] 
but can accelerate degenerative changes in adjacent 
discs and have poor outcomes [6, 7]. New approaches in 
tissue engineering have provided a variety of potential 
treatment options [8]. However current progress in MSC 
based therapies are hampered by a lack of understanding 
and consensus of the normal nucleus pulposus (NP) cell 
phenotype [9]. Considerable progress in understanding 
the ontogeny and physiology of NP cells has occurred 
over the last decade with a resultant plethora of marker 
genes identified to distinguish NP from annulus fibrosus 
(AF) and articular chondrocytes (AC) [9-14]. Risbud 
et al., (2015) recently reported NP phenotypic markers 
recommended for use in directing MSC based regeneration 
strategies for the NP [9]; this paper focused on defining the 
young healthy NP cell phenotype, as they hypothesised 
this cell type would be most successful in terms of NP 
regeneration as a treatment strategy for LBP [9]. However, 
despite this consensus paper, there is still a need to further 
validate, at gene and protein level, proposed NP markers 
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which have been identified from transcription expression 
profiles or assessed at protein level but only in a small 
number of human samples; such molecules include: paired 
box protein 1 (PAX1), forkhead box f1 (FOXF1) [10, 15] 
and ovostatin-2 (OVO-2) [10] as well as the proposed 
NP negative marker Integrin binding sialoprotein (IBSP)
[10], shown to be differentially expressed between NP 
and AC cells. Moreover the potential for matrix binding 
proteins to act as indicators of the NP ECM warrant 
further investigation. Namely laminin-332 (laminin-5) 
and laminin-511 (laminin 10) which have been previously 
shown to be expressed highly in rat and porcine NP tissue 
in comparison to annulus fibrosus (AF) tissue, however to 
date this has not been investigated in human IVD tissue 
[16, 17]. 
The aim of this study was to further validate the 
use of proposed NP specific markers on a large cohort of 
human NP and AC samples, at mRNA and protein level 
using qRT-PCR and immunohistochemistry. To determine 
whether an NP phenotypic profile could be identified 
within a large population of mature NP samples.
RESULTS
qRT-PCR analysis 
Previously identified ‘marker’ genes SHH, 
Brachyury, GLUT-1, CA12, KRT18, KRT19, CD24 
(Figure 1), FOXF1, PAX1, LAM-511 (identified by α5) 
LAM-332 (identified by γ2), OVO-2 as well as IBSP 
(Figure 2), a proposed negative NP marker, were assessed 
for mRNA expression using qRT-PCR. No significant 
difference in the levels of mRNA expression were 
observed between AC compared with non-degenerate NP 
cells with the exception of PAX1 and FOXF1 (Figures 1 
& 2). 
The proportion of samples found to be expressing 
KRT-18 was significantly lower (P=0.0099) in AC 
samples compared with NP samples (Figure 1). The 
proportion of samples found to be expressing LAM-A5 
was also significantly higher in moderate (4-7) (P=0.0086) 
and severely degenerate NP cells (>7) (P=0.0171) in 
comparison to AC cells (P=0.0317) (Figure 2). The 
notochordal markers SHH and brachyury were expressed 
in a small proportion of NP samples, with no expression 
detected in the non-degenerate (<4) NP sample cohort 
(Figure 1). The proportion of samples found to be 
positive for IBSP mRNA expression was significantly 
higher (P=0.0263) in moderately degenerate (4-7) NP 
samples compared with AC samples (Figure 2). PAX1 
and FOXF1 showed significantly higher expression levels 
in NP cells in comparison to AC cells (PAX1: P=0.0003) 
(FOXF1: P=0.0049) accompanied by a significantly 
higher proportion of samples (PAX1: P=0.0024) (FOXF1: 
P=0.0067) in NP samples compared with AC samples, 
regardless of degeneration grade (Figure 2). 
Differential protein expression within the 
anatomical regions of the IVD
KRT-19 protein was expressed at low levels 
throughout all anatomical regions of the IVD and was 
significantly higher in in the NP in comparison to the CEP 
(P≤0.05) (Figures 3 & 4). LAM-5 (LAM-332) protein 
expression was detected in all regions with significantly 
higher expression levels in the NP (P=0.0001) and 
AF (P=0.0001) in comparison to the CEP, however no 
significant difference in the expression of LAM-5 protein 
was observed between the AF and NP (Figures 3 & 4). 
PAX1 and FOXF1 protein were expressed in all regions 
of the IVD and were significantly higher in the AF (PAX: 
P=0.0001; FOXF1: P=0.003) and NP (PAX: P=0.0001; 
FOXF1: P=0.0001) in comparison to the CEP and also 
significantly higher in the NP (PAX: P=0.0001; FOXF1: 
P= 0.0001) compared to the AF (Figures 3 & 4). 
Immunohistochemical validation of NP marker 
genes in human AC and NP samples
Within surgical samples PAX1 and FOXF1 protein 
was expressed in 100% of NP samples and 60% of AC 
(PAX1) and 80% of AC (FOXF1) samples (Figures 5 & 
6). The expression of PAX1 and FOXF1 was significantly 
higher in NP samples in comparison to AC samples 
regardless of grade of degeneration (P≤0.05) (Figure 6). 
HIF1α protein was expressed in 100% of NP and AC 
samples (Figure 6). No significant difference in the protein 
expression of HIF1α was observed between AC and NP 
samples (Figure 6). 
DISCUSSION
NP markers indicative of NP ontongeny
The origin of NP cells is currently an unresolved 
area of IVD research. Compelling evidence indicates 
that mature NP cells of the adult IVD have differentiated 
along the notochordal lineage [30], however existing 
evidence which supports the migration of CEP and AF 
cells should not be ignored [31, 32]. The notochordal 
origin is reflected in the recommended markers SHH and 
brachyury expressed in the developing notochord [33-
35]. Decreased SHH and brachyury expression have been 
shown to correlate with aging and degeneration which 
agrees with the low proportion of samples expressing 
SHH and brachyury in this study, which could be due 
to the age of patient samples enrolled in this study (20-
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Figure 1: Markers recommended for use in defining the young healthy NP phenotype. qRT-PCR mRNA expression from 
directly extracted articular chondrocytes (AC), histologically non degenerate (<6) and directly extracted nucleus pulposus (NP) cells, graded 
histologically as non-degenerate (<4); moderately degenerate (4-7); severely degenerate (>7) and those containing infiltrated cells (Inf). 
Percentage of positive samples displayed above. (*) significant difference in expression levels between AC and NP cells. (+) Significant 
difference in proportion of samples expressing target gene in NP samples compared to AC samples: P = ≤0.05.
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71yrs).[36] Recently, however Wnt mediated reactivation 
of SHH signalling has been shown to increase expression 
of brachyury, aggrecan and chondroitin sulphate in aged 
discs [37]. Expression of brachyury has also been reported 
in the mature NP [11, 36]. The lack of notochordal cells 
within the mature healthy adult NP must be considered 
when developing regenerative treatment strategies for 
IVD degeneration, since transplanted cells need to be 
capable of withstanding the altered microenvironmental 
cues in the mature NP. An ideal phenotypic NP marker 
would be one which is NP specific, reflects NP ontogeny 
and is consistently expressed in healthy mature NP cells, 
which populate and survive in the adult IVD. Having 
said this, using markers which reflect NP ontogeny, to 
inform differentiation of regenerative cells into NP cells 
is likely to be problematic since a lack of expression of 
Figure 2: Proposed NP markers for further investigation. qRT-PCR mRNA expression from directly extracted articular 
chondrocytes (AC), histologically non degenerate (<6) and directly extracted nucleus pulposus (NP) cells, graded histologically as non-
degenerate (<4); moderately degenerate (4-7); severely degenerate (>7) and those containing infiltrated cells (Inf). Percentage of positive 
samples displayed above. (*) significant difference in expression levels between AC and NP cells. (+) Significant difference in proportion 
of samples expressing target gene in NP samples compared to AC samples: P = ≤0.05.
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such markers does not necessarily demonstrate that the 
regenerative cells being used are not differentiating into 
NP cells, it may simply demonstrate that the regenerative 
cells are not from the same ontogeny as NP cells. 
NP markers indicative of NP physiology
The NP is the largest avascular tissue in the human 
body and thus NP cells are physiologically adapted to 
survive in a hypoxic microenvironment, mediated by the 
expression of HIF1α [27, 29, 38]. HIF-1α drives glycolytic 
metabolism and supports the function and survival of 
NP cells by inducing the up-regulation of GAPDH, 
GLUT1/3, galectin-3, glucuronyltransferase-1 and 
vascular endothelial growth factor-A (VEGF-A) [28, 29]. 
GLUT-1 in particular, has been included alongside HIF1α 
as a recommended marker, reflective of NP physiology 
[9, 14]. However no differential expression was observed 
between AC and NP cells for GLUT1 or HIF1α. Similarly 
CA12, a physiological marker which reflects the ability 
of NP cells to buffer the elevated lactic acid found in 
Figure 3: Immunohistochemistry of post mortem intervertebral disc samples. IHC of PAX1, FOXF1, LAM-5 and KRT-19 
on post mortem samples, CEP (cartilaginous end plate), AF (annulus fibrosus) and NP (nucleus pulposus). Positive cells indicated by black 
arrows, negative cells indicated by white arrows. Scale bar 50µm.
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Figure 4: Immunopositive quantification of post mortem intervertebral disc samples. Thompson grades 1-5. 200 cells 
counted per anatomical region and % immunopositivity calculated. (*) Significance indicated between expression levels P ≤ 0.05.
Figure 5: Immunohistochemistry of surgical intervertebral disc samples. PAX1, FOXF1 and HIF1α on articular cartilage 
(AC) histologically graded as non-degenerate (<6) and nucleus pulposus (NP) tissue surgically removed following discectomy graded 
histologically as non-degenerate (<4); moderately degenerate (4-7) and severely degenerate (>7). Positive cells indicated by black arrows, 
negative cells indicated by white arrows. Scale bar 50µm.
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this tissue, [39] was also expressed in AC and NP cells 
with no significant difference in expression levels. Akin 
to the NP, AC is an avascular, hypoxic environment[40], 
and HIF-1α is crucial for AC cell survival [41]. Thus, 
although physiological markers are essential to assess the 
ability of differentiated cells to respond appropriately to 
the harsh NP microenvironment, they are not NP specific. 
Interestingly however NP cells uniquely constitutively 
express HIF1α even in the presence of oxygen [27]. NP 
cell differentiation assessment could focus on constitutive 
HIF1α expression under hypoxic and normoxic culture 
conditions as opposed to simply expression of the protein. 
Differentially expressed markers recommended 
for use in defining the NP phenotype
Microarray studies by Fujitta et al., 2005 identified 
the expression of the heat-stable antigen CD24, in rat NP 
cells, which was later replicated in subsequent studies [42, 
43]. Despite this, differential expression of CD24 was not 
confirmed in human samples in this study, in agreement 
with Rutges et al., 2010 who reported that CD24 was 
not differentially expressed [12]. KRT-18 (canine) 
and KRT-19 (rat) were also identified as differentially 
expressed between NP and AC cells [25], which was 
confirmed in bovine IVDs [11]. However, these results 
failed to translate to human samples in this study with no 
significant difference observed. KRT-19 is expressed in the 
embryonic notochord [44] and has been shown to decrease 
with age [12] which could explain the differential results 
in this study. Although KRT-18 was seen in human NP 
samples 67% of AC samples also showed expression, thus 
the use of this marker alone lacks NP specificity. 
Differentially expressed markers between NP and 
AC which require further investigation
A multitude of proposed genes have been identified 
as NP phenotypic markers, those which are less well 
validated include the OVO-2[10], FOXF1 [10, 15] and 
PAX1 [10, 15]. Additionally LAM-332 (LAM-5) and 
LAM-511 (LAM-10) have recently been shown to be 
differentially expressed between porcine and rat NP and 
AF [17]. Furthermore it may also be useful to include 
NP negative, AC positive markers in a panel which 
assesses the phenotypic profile of differentiating cells 
to NP-like cells, such as IBSP [10]. Unlike previous 
studies OVO2, LAM-511 (identified by the α5 subunit), 
LAM-332 (identified by the ᵧ2 chain), and IBSP were not 
differentially expressed at mRNA level between NP and 
AC in human samples. The higher protein expression of 
LAM-5 in NP compared to AF reported previously[16] 
was not replicated in human samples in this study, 
however the LAM-5 antibody used recognises the α3 
subunit and thus may also recognise LAM-6/7. A variety 
of studies have published conflicting data on marker genes 
proposed as being differentially expressed between NP 
and AC; this could be due to species variation and/or small 
sample sizes. 
Previously reported novel NP marker genes, 
PAX1 and FOXF1 were validated by qRT-PCR and 
immunohistochemistry as being more highly expressed in 
the NP than AC [10, 15]. Interestingly, protein expression 
of PAX1 and FOXF1 were also higher in NP than both AF 
and the CEP, shown here for the first time in native tissue; 
supported recently by Van den Akker et al., 2014, where 
human NP and AF cell populations were extracted from 
non-degenerate healthy IVDs and were shown to express 
PAX1 and FOXF1 more highly in extracted NP compared 
to AF cells [15]. Higher expression of FOXF1 in NP cells 
Figure 6: Immunopositive quantification of surgical intervertebral disc samples. Immunohistochemistry of PAX1, FOXF1 
and HIF1α on articular cartilage (AC) histologically non degenerate (<6) and nucleus pulposus (NP) tissue graded histologically as non-
degenerate (<4); moderately degenerate (4-7) and severely degenerate (>7). Percentage of positive samples displayed above. (*) indicates 
significance between % immunopositivity of NP compared to AC. (+) Indicates significance between proportion of NP samples found to be 
expressing target protein, compared to AC samples P = ≤0.05.
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compared to AC cells has been previously reported [10, 
15], but the exact role of FOXF1 in the human IVD is yet 
to be elucidated. The role of FOXF1 in cell proliferation, 
differentiation and cell survival is well established[45-47]. 
FOXF1 gene deletions have been associated with birth 
defects including spinal malformations and fusion of the 
vertebrae [48]. PAX1 expression in the IVD has been 
previously reported in young adult mice [49], in the 
human fetal vertebral column [50] and in the human NP 
[10], however, the exact role of PAX1 within the NP is 
unknown.
Both PAX1 and FOXF1 can be activated by SHH 
signalling. [51] PAX1 is regulated by SHH signalling 
and is often used to illustrate continued SHH signalling 
in sclerotome development [52]. While SHH is not 
necessary for the induction of PAX1, SHH knockout mice 
lack vertebral structures and quickly lose PAX1 expression 
[53], thus, the loss of SHH expression in mature adult NP 
cells could alter the expression of PAX1 in human NP 
cells. Although PAX1 expression has previously been 
associated as a marker of sclerotomal cells and is highly 
expressed in the AF, shown in mouse models [49, 54], 
studies which assess the expression of PAX1 and FOXF1 
during human IVD development and in the different 
anatomical regions of the IVD are lacking. Whether the 
high expression of PAX1 and FOXF1 shown here in 
mature human NP cells reflects NP cell ontogeny, possible 
migration of cells from adjacent tissues, or is a functional 
marker of mature adult NP cells, remains to be elucidated. 
Despite limited understanding of the role of PAX1 
and FOXF1 in the human NP, this study demonstrated 
differential expression by NP cells which did not increase 
with degeneration grade; thus the exact role of PAX1 and 
FOXF1 within the NP warrants further investigation and 
both should be considered for use in defining the adult 
NP cell phenotype. Noteworthy, however is the fact that 
although expression levels were higher in NP cells, AC 
and AF cells were shown to express PAX1 and FOXF1; 
thus it is vital that such molecules are only used within a 
panel of NP markers thus providing a phenotypic profile 
which reflects the ontogeny, physiology and function of 
NP cells. 
CONCLUSIONS
A marker which exclusively differentiates NP cells 
from AF and AC cells remains to be identified, raising 
the question: is the NP a heterogeneous population of 
cells? Or does the natural biological variation during IVD 
development, degeneration state and even the life cycle 
of cells make finding one definitive marker impossible? 
From a clinical perspective the aim is to restore/maintain 
spine biomechanics and alleviate patient symptoms; thus 
the ability of differentiated cells to recapitulate the NP 
ECM (aggrecan to collagen type II ratio >20) and NP 
biomechanics should be the prime focus when developing 
treatment strategies for regeneration of the IVD, as 
opposed to the expression of NP phenotypic markers.  
MATERIALS AND METHODS
Human IVD tissue
Human IVD tissue was obtained from surgery or 
PM examination (processed within 72 hours after death) 
with informed consent of the patients or relatives. Ethical 
approval was obtained from Sheffield Research Ethics 
Committee (09/H1308/70), and department of Pathology/
UMCU Biobank, UMC Utrecht (Supplementary Table I/
II). 
Human articular cartilage tissue
Human articular cartilage (AC) samples were 
obtained from patients undergoing total knee replacement 
surgery with informed consent of the patient or relatives 
(Supplementary Table III). Cartilage was obtained under 
the National Research Ethics Service approval held by 
the Sheffield Musculoskeletal Biobank. AC was obtained 
from various anatomical compartments within the knee 
(medial and lateral tibio-femoral and patello-femoral 
compartments) for 10 surgical AC samples. Cartilage 
tissue was graded macroscopically 0–4 using the 
Outerbridge classification [18]. All AC samples used in 
this study were macroscopically graded as non-degenerate 
(grade 0-1).
Tissue processing
IVD tissue
IVD tissues processed at Sheffield Hallam 
University (SHU) were separated into two and either fixed 
in 10% neutral buffered formalin (Leica, Milton Keynes 
UK) and processed to paraffin wax (Leica) or processed 
for cell extraction. Following paraffin wax embedding, 
4μm sections were cut, mounted onto positively charged 
slides (Leica) and IVD tissue histologically graded using 
previously published criteria [19, 20]. NP tissue free from 
contaminating AF and CEP was digested in protease 
and collagenase to isolate cells and RNA extracted as 
previously published [21]. IVD Tissue processed at 
Utrecht was decalcified and embedded to paraffin wax 
as previously published [22]. Four micron sections were 
histologically graded using previously published criteria 
[19, 20].
AC tissue
AC tissue was separated into two and either fixed in 
10% v/v neutral buffered formalin (Leica) and processed 
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to paraffin wax, or processed for cell extraction. Following 
paraffin wax embedding, 4μm sections were histologically 
graded based on the Mankin [23] grading system with 
the addition of abnormal features and cartilage thickness 
also assessed. Cells were extracted using trypsin and 
collagenase as previously published [24], and cells were 
used for direct RNA extraction using TRIZOL reagent and 
cDNA synthesised.
Real-time quantitative polymerise chain reaction 
(qRT-PCR)
Target genes were investigated using quantitative 
real-time polymerase chain reaction (qRT-PCR) conducted 
on 10 non-degenerate AC samples (microscopic grade 
0-6), 11 non-degenerate NP samples (grade <4), 24 
moderately degenerate NP samples (grade 4 -7), 18 
severely degenerate NP samples (grade >7) and 18 NP 
samples with evident infiltration (Supplementary Table I, 
II, III).
qRT-PCR was performed on a StepOnePlus™ Real-
Time PCR System (Applied Biosystems, Lutterworth 
UK) for potential NP markers (Pre-designed primer/
probe mixes Applied Biosystems) (Supplementary 
Table IV). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and 18S (Applied Biosystems) were used 
as housekeeping genes. Ten microliter reactions were 
prepared using TaqMan Universal PCR Master Mix 
(Applied Biosystems). Results were analysed using the 
2-ΔCt method and presented as relative gene expression 
normalised to the average CT for the two housekeeping 
genes.
Immunohistochemistry
Immunohistochemistry (IHC) was conducted 
on PM samples from the department of Pathology/
UMCU Biobank, UMC Utrecht, Thompson grades 
1-5 (n=4/5) to assess protein expression within each of 
the anatomical regions (CEP, AF, NP) of the IVD. IHC 
analysis was undertaken for PAX1 and FOXF1, found to 
be differentially expressed at gene level (Figure 2), KRT-
19 due to its extensive use as an NP marker in a variety of 
studies [10, 12, 25] and LAM-5 (LAM-332) to determine 
whether the differential expression observed between NP 
and AF in porcine tissue correlated with human tissue [16, 
17]. Further IHC analysis of PAX1 and FOXF1, shown 
to be differentially expressed within the NP compared to 
both the AF and CEP (Figures 3 & 4) and HIF1α shown to 
be essential to the physiology of NP cells and regulated at 
protein level [26-29], was conducted on a larger subset of 
surgical samples (NP: n=30; AC: n=10) (Supplementary 
Table I/III) to investigate differential expression between 
NP and AC tissue.  
Sections were prepared as described for histological 
analysis; IHC was performed as previously described, 
[19] specific antigen retrieval, serum block, and antibody 
details shown in Supplementary Table V. All slides were 
visualised using an Olympus BX51 microscope and 
images captured by digital camera and Capture Pro OEM 
v8.0 software (Media Cybernetics, Buckinghamshire, 
UK). Evaluation of IHC staining was performed by 
counting 200 cells within each anatomical region (NP, AF, 
CEP or AC) on each section, with immunopositive cells 
expressed as a percentage of total count.
Statistical analysis
Data were shown to be non-parametric and hence 
a Kruskall-Wallis with Conover-Inman post hoc analysis 
test was used to identify significant differences between 
AC compared with NP samples, as well as differences 
between NP degeneration grade, investigated by qRT-
PCR and IHC (P≤0.05). Two independent proportionality 
tests were performed to identify differences between the 
proportions of samples expressing the target molecules at 
mRNA and protein level (P≤0.05). 
Abbreviations
MSC, mesenchymal stem cell; LBP, low back 
pain; NP, nucleus pulposus; AF, annulus Fibrosus; CEP, 
cartilagenous endplate; AC, articular chondrocyte; SHH, 
sonic hedgehog; GLUT-1, glucose transporter 1; CA12, 
carbonic anhydrase XII; KRT18, Keratin 18; KRT19, 
Keratin 19; CD24, Cluster of differentiation 24; FOXF1, 
Forkhead Box F1; PAX1, Paired Box 1; LAMA5, Laminin 
Alpha 5; LAMC2, Laminin gamma 2; LAM5/332, 
Laminin 5/332; LAM10/511, Laminin, 10/511; OVO-2, 
Ovostatin 2; IBSP, Integrin Binding Sialoprotein; HIF1α, 
Hypoxia-inducible factor 1-alpha.
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